STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
MergerMay 1, 2026, 04:37 PM

Masimo to be Acquired by Danaher; 2025 Annual Bonus 113% of Target

AI Summary

Masimo filed an Amendment No. 1 to its Form 10-K for fiscal year 2025 to include previously omitted Part III information, detailing directors, executive officers, corporate governance, and executive compensation. The filing also disclosed a merger agreement with Danaher Corporation on February 16, 2026, under which Masimo will be acquired. For fiscal 2025, the company's annual cash bonus was earned at 113% of target, while 2023 PSUs were earned at 18% of target.

Key Highlights

  • Merger Agreement with Danaher Corporation on February 16, 2026.
  • Masimo is a large accelerated filer.
  • Market value of non-affiliate voting stock was approximately $3.9 billion on June 28, 2025.
  • CEO Catherine Szyman's 2025 base salary set at $1,000,000.
  • 2025 annual cash bonus earned at 113% of target.
  • 2023 Performance Stock Units (PSUs) earned at 18% of target.
  • Interim CEO Michelle Brennan received a bonus of $1,087,190.
  • Adjusted Revenue performance was $1,509 million (99% of target).
MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
MASIMO CORP

Price Impact